TD Cowen Reiterates Buy Rating on DexCom (DXCM)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $100.00 price target on DexCom (NASDAQ: DXCM).

The analyst commented, "DXCM reported 3Q results which were slightly ahead of Street revenue and EPS expectations. Importantly, management's commentary suggests that US market headwinds may have peaked in 3Q and should moderate going forward. This, combined with progress in the company's pipeline (Stelo launch, 15-day G7 submission), drives our optimism towards improving performances in the coming quarters."

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $74.85 yesterday.

You May Also Be Interested In

• J Capital Research cautious on Microchip: 'riding high on AI hype but looks weak'
• Neucleus Group files for IPO on Nasdaq at $4-$5 per share
• Freedom Broker Starts M/I Homes (MHO) at Buy